The Association of PLAUR Genotype and Soluble suPAR Serum Level with COVID-19-Related Lung Damage Severity

Int J Mol Sci. 2022 Dec 19;23(24):16210. doi: 10.3390/ijms232416210.

Abstract

Uncovering the risk factors for acute respiratory disease coronavirus 2019 (COVID-19) severity may help to provide a valuable tool for early patient stratification and proper treatment implementation, improving the patient outcome and lowering the burden on the healthcare system. Here we report the results of a single-center retrospective cohort study on 151 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected symptomatic hospitalized adult patients. We assessed the association of several blood test measurements, soluble urokinase receptor (uPAR) serum level and specific single nucleotide polymorphisms of ACE (I/D), NOS3 (rs2070744, rs1799983), SERPINE1 (rs1799768), PLAU (rs2227564) and PLAUR (rs344781, rs2302524) genes, with the disease severity classified by the percentage of lung involvement on computerized tomography scans. Our findings reveal that the T/C genotype of PLAUR rs2302524 was independently associated with a less severe lung damage (odds ratio 0.258 [0.071-0.811]). Along with high C-reactive protein, fibrinogen and soluble uPAR serum levels turned out to be independently associated with more severe lung damage in COVID-19 patients. The identified factors may be further employed as predictors of a possibly severe COVID-19 clinical course.

Keywords: COVID-19; PLAUR; candidate polymorphism study; rs2302524; soluble uPAR.

MeSH terms

  • Adult
  • COVID-19* / genetics
  • Genotype
  • Humans
  • Lung* / pathology
  • Receptors, Urokinase Plasminogen Activator* / blood
  • Receptors, Urokinase Plasminogen Activator* / genetics
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Receptors, Urokinase Plasminogen Activator
  • PLAUR protein, human